ImmunityBio (IBRX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
The meeting was held virtually for the seventh consecutive year, allowing real-time online voting until polls closed.
Directors, officers, the independent auditor, and legal counsel were present virtually.
The meeting followed company bylaws and Delaware law, with notice and proxy materials distributed to stockholders.
Board and executive committee updates
Nine incumbent directors were nominated for re-election to serve until the 2027 annual meeting.
No stockholder nominations for director were received in advance.
Shareholder proposals
The agenda included the election of directors and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from ImmunityBio
- ANKTIVA delivers durable cancer responses, drives global growth, and expands into new indications.IBRX
Jefferies Global Healthcare Conference 20264 Jun 2026 - Q1 2026 revenue surged 168% to $44.2M, but net loss deepened to $632.8M on non-cash charges.IBRX
Q1 20267 May 2026 - Director elections and auditor ratification headline the June 2026 virtual shareholder meeting.IBRX
Proxy filing30 Apr 2026 - Record revenue growth, global approvals, and robust governance highlight this year's proxy.IBRX
Proxy filing30 Apr 2026 - 700% revenue growth to $113M, global expansion, and net loss narrowed to $351M.IBRX
Q4 202530 Apr 2026 - Global immunotherapy expansion accelerates with durable clinical results and new market launches.IBRX
The Citizens Life Sciences Conference 202628 Apr 2026 - ANKTIVA drives global immunotherapy growth with strong efficacy, approvals, and financial momentum.IBRX
Investor presentation11 Mar 2026 - FDA approval, robust NMIBC efficacy, and global expansion drive strong growth.IBRX
Investor Day 20253 Feb 2026 - Stockholders will vote on director elections, a new equity plan, and auditor ratification.IBRX
Proxy Filing1 Dec 2025